ALLK
Price:
$0.3291
Market Cap:
$29.74M
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; ...[Read more]
Industry
Biotechnology
IPO Date
2018-07-19
Stock Exchange
NASDAQ
Ticker
ALLK
According to Allakos Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.42. This represents a change of -102.40% compared to the average of 17.56 of the last 4 quarters.
The mean historical PE Ratio of Allakos Inc. over the last ten years is -25.48. The current -0.42 PE Ratio has changed 65.58% with respect to the historical average. Over the past ten years (40 quarters), ALLK's PE Ratio was at its highest in in the December 2024 quarter at 71.96. The PE Ratio was at its lowest in in the June 2017 quarter at -54.94.
Average
-25.48
Median
-23.81
Minimum
-60.30
Maximum
-0.93
Discovering the peaks and valleys of Allakos Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 112.00%
Maximum Annual PE Ratio = -0.93
Minimum Annual Increase = -95.67%
Minimum Annual PE Ratio = -60.30
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -0.93 | -27.28% |
| 2023 | -1.28 | -23.40% |
| 2022 | -1.67 | -14.72% |
| 2021 | -1.95 | -95.67% |
| 2020 | -45.15 | -10.56% |
| 2019 | -50.48 | 112.00% |
| 2018 | -23.81 | -45.61% |
| 2017 | -43.78 | -27.39% |
The current PE Ratio of Allakos Inc. (ALLK) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.29
5-year avg
-10.19
10-year avg
-25.48
Allakos Inc.’s PE Ratio is greater than Harpoon Therapeutics, Inc. (-1.14), less than LianBio (4.68), less than Metacrine, Inc. (-0.40), less than Freeline Therapeutics Holdings plc (-0.29), greater than Marinus Pharmaceuticals, Inc. (-0.52), greater than Elevation Oncology, Inc. (-0.45), greater than Kineta, Inc. (-0.96), less than Applied Genetic Technologies Corporation (-0.25), less than Odonate Therapeutics, Inc. (3.23K), less than Angion Biomedica Corp. (-0.27),
| Company | PE Ratio | Market cap |
|---|---|---|
| -1.14 | $865.08M | |
| 4.68 | $11.68M | |
| -0.40 | $0 | |
| -0.29 | $28.28M | |
| -0.52 | $30.37M | |
| -0.45 | $21.63M | |
| -0.96 | $7.05M | |
| -0.25 | $0 | |
| 3.23K | $24.14B | |
| -0.27 | $30.11M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Allakos Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Allakos Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Allakos Inc.'s PE Ratio?
How is the PE Ratio calculated for Allakos Inc. (ALLK)?
What is the highest PE Ratio for Allakos Inc. (ALLK)?
What is the 3-year average PE Ratio for Allakos Inc. (ALLK)?
What is the 5-year average PE Ratio for Allakos Inc. (ALLK)?
How does the current PE Ratio for Allakos Inc. (ALLK) compare to its historical average?